





Restylane

ESTABLISHED SAFETY PROFILE

HCPs around the world rely on the natural elegance of *Restylane*

A rich heritage born of the Swedish ideals of natural beauty, with a legacy of continuous innovation and development



The world's first stabilized non-animal hyaluronic acid (HA) filler

Over 40 publications based on randomized controlled trials

Two unique technologies (OBT™ and NASHA™) to provide a treatment for every patient need

Over 150 scientific publications




Over 40 million syringes administered worldwide



1996

Fillers designed for specific treatment purposes





Decades of clinical experience and safety follow-up



Over 20 years of dermal filler leadership and expertise

Over 3000 patients followed in clinical trials

BROADEST HA FILLER PORTFOLIO

Individualise treatment with the world's broadest portfolio of fillers



Brings together two unique technologies (OBT and NASHA) for the broadest range of gel textures

Optimal Balance Technology (OBT) creates a softer gel texture



NASHA creates a firmer gel texture

- Softer gel with controlled and homogenous particle size with an HA concentration of 20 mg/mL
- Gel texture with less pronounced lifting capacity
- Distributed product integration in the tissue
- For patients with poorer tissue quality, where a softer product gives the optimal result

- Firmer gel with controlled and homogenous particle size with an HA concentration of 20 mg/mL
- Gel texture with more pronounced lifting capacity
- Targeted product integration in the tissue
- For patients with better tissue quality, where a firm product gives the optimal result



Restylane Fynesse



Restylane Refyne



Restylane Kysse



Restylane



Restylane Defyne




Restylane Lyft



Restylane Volyme





















Restylane Defyne

Restylane Lyft

Restylane Kysse







Restylane Classic

Restylane Volyme


BROADEST HA FILLER PORTFOLIO

RESTORE

Restylane Refyne Restylane Volyme Restylane Fynesse Restylane (Emervel Classic) (Emervel Volume) (Emervel Touch) 20 mg/mL cross-linked 20 mg/mL cross-linked 20 mg/mL stabilised hyaluronic 20 mg/mL cross-linked hyaluronic acid, phosphate hyaluronic acid, phosphate acid, phosphate buffered saline, Composition hyaluronic acid, phosphate buffered saline, buffered saline, with 0.3% lidocaine buffered saline with 0.3% lidocaine with 0.3% lidocaine Treatment areas Nasolabial and Nasolabial and Cheek Periorbital and perioral marionette marionette Injection depth Onset Immediate Immediate Immediate Immediate of action **Estimated** Up to 18 months1* Up to 18 months^{2*} Up to 18 months³ Up to 6 months⁴ duration

- 1. Narins et al., Dermatol Surg 2008;34:S2-S8
- 2. Galderma data on file (Study ID 40073) 3. Talarico et al., Dermatol Surg 2015;41:1361-1369 4. Rzany et al., J Drugs Dermatol. 2012;11(1)(suppl):s27-s34


ENHANCE



- 5. Galderma data on file (Study ID MA-1400-05)
- 6. Galderma data on file (Study ID 40072) 7. Cartier et al., J Drugs Dermatol. 2012;11(1)(suppl):s17-s26



Restylane enables you to tailor your patients treatment based on tissue quality, desired outcome, and treatment area



Measures how resistant viscoelastic materials (such as gels) are to deformation G^* is the sum of elastic modulus (G') and viscous modulus (G'').

Naturally Restylane

The choice to create the natural results your patients desire

- Individualised treatments with the world's broadest portfolio of HA fillers
- Established safety profile based on over 2 decades of experience
- High patient satisfaction with more than 40 million treatments world wide

